Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
KRASG12C
chemotherapy
combination therapy
immunotherapy
non-small cell lung cancer
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
04
04
2023
accepted:
01
06
2023
medline:
8
11
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination with platinum-doublet chemotherapy (chemo-immunotherapy). Outcomes to chemo-immunotherapy in this subgroup have not been well described. Our goal was to define the clinical outcomes to chemo-immunotherapy in patients with NSCLC with KRASG12C mutations. Through next-generation sequencing, we identified patients with advanced NSCLC with KRAS mutations treated with chemo-immunotherapy at 2 institutions. The primary objective was to determine outcomes and determinants of response to first-line chemo-immunotherapy among patients with KRASG12C by evaluating objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). We assessed the impact of coalterations in STK11/KEAP1 on outcomes. As an exploratory objective, we compared the outcomes to chemo-immunotherapy in KRASG12C versus non-G12C groups. One hundred and thirty eight patients with KRASG12C treated with first-line chemo-immunotherapy were included. ORR was 41% (95% confidence interval (CI), 32-41), median PFS was 6.8 months (95%CI, 5.5-10), and median OS was 15 months (95%CI, 11-28). In a multivariable model for PFS, older age (P = .042), squamous cell histology (P = .008), poor ECOG performance status (PS) (P < .001), and comutations in KEAP1 and STK11 (KEAP1MUT/STK11MUT) (P = .015) were associated with worse PFS. In a multivariable model for OS, poor ECOG PS (P = .004) and KEAP1MUT/STK11MUT (P = .009) were associated with worse OS. Patients with KRASG12C (N = 138) experienced similar outcomes to chemo-immunotherapy compared to patients with non-KRASG12C (N = 185) for both PFS (P = .2) and OS (P = .053). We define the outcomes to first-line chemo-immunotherapy in patients with KRASG12C, which provides a real-world benchmark for clinical trial design involving patients with KRASG12C mutations. Outcomes are poor in patients with specific molecular coalterations, highlighting the need to develop more effective frontline therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination with platinum-doublet chemotherapy (chemo-immunotherapy). Outcomes to chemo-immunotherapy in this subgroup have not been well described. Our goal was to define the clinical outcomes to chemo-immunotherapy in patients with NSCLC with KRASG12C mutations.
PATIENTS AND METHODS
METHODS
Through next-generation sequencing, we identified patients with advanced NSCLC with KRAS mutations treated with chemo-immunotherapy at 2 institutions. The primary objective was to determine outcomes and determinants of response to first-line chemo-immunotherapy among patients with KRASG12C by evaluating objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). We assessed the impact of coalterations in STK11/KEAP1 on outcomes. As an exploratory objective, we compared the outcomes to chemo-immunotherapy in KRASG12C versus non-G12C groups.
RESULTS
RESULTS
One hundred and thirty eight patients with KRASG12C treated with first-line chemo-immunotherapy were included. ORR was 41% (95% confidence interval (CI), 32-41), median PFS was 6.8 months (95%CI, 5.5-10), and median OS was 15 months (95%CI, 11-28). In a multivariable model for PFS, older age (P = .042), squamous cell histology (P = .008), poor ECOG performance status (PS) (P < .001), and comutations in KEAP1 and STK11 (KEAP1MUT/STK11MUT) (P = .015) were associated with worse PFS. In a multivariable model for OS, poor ECOG PS (P = .004) and KEAP1MUT/STK11MUT (P = .009) were associated with worse OS. Patients with KRASG12C (N = 138) experienced similar outcomes to chemo-immunotherapy compared to patients with non-KRASG12C (N = 185) for both PFS (P = .2) and OS (P = .053).
CONCLUSIONS
CONCLUSIONS
We define the outcomes to first-line chemo-immunotherapy in patients with KRASG12C, which provides a real-world benchmark for clinical trial design involving patients with KRASG12C mutations. Outcomes are poor in patients with specific molecular coalterations, highlighting the need to develop more effective frontline therapies.
Identifiants
pubmed: 37589215
pii: 7243567
doi: 10.1093/oncolo/oyad197
pmc: PMC10628591
doi:
Substances chimiques
Kelch-Like ECH-Associated Protein 1
0
Platinum
49DFR088MY
NF-E2-Related Factor 2
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-985Subventions
Organisme : NCI NIH HHS
ID : R01 CA279264
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA230267
Pays : United States
Organisme : NIH HHS
ID : P30-CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA230745
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA129243
Pays : United States
Organisme : NIH HHS
ID : P30-CA008748
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
JAMA Oncol. 2022 Feb 01;8(2):287-291
pubmed: 34734967
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
Clin Cancer Res. 2020 Jan 1;26(1):274-281
pubmed: 31548347
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
JCO Precis Oncol. 2019;3:
pubmed: 31832578
Lung Cancer. 2019 Jul;133:144-150
pubmed: 31200821
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730
J Clin Oncol. 2022 Aug 10;40(23):2609-2611
pubmed: 35763705
BMC Med Genomics. 2017 May 19;10(1):33
pubmed: 28526081
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
Cell. 2020 Nov 12;183(4):850-859
pubmed: 33065029
Clin Cancer Res. 2021 Apr 15;27(8):2209-2215
pubmed: 33558425
Nature. 2021 Nov;599(7886):679-683
pubmed: 34759319
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704